Barcelona– November 12, 2025 –Meta Cell Technology, a pioneer in autologous exosome science, introduces an advancement to its MCT exosome protocols: the integration of the first injectable exosome bioimplant, designed to optimize outcomes and enhance exosome bioactivity.
Exo-Tech transforms the patient’s plasma into an injectable, viscoelastic scaffold enriched with MCT exosomes prepared using the MCT System. The result is a next-generation exosome bioimplant that provides structural support and sustained regenerative signaling.
A New Standard in Exosome Delivery
Exo-Tech creates a structured protein scaffold that acts as a local reservoir, gradually releasing exosomes and growth factors over time—prolonging regenerative activity at the target site.
Together, the MCT System and Exo-Tech deliver an injectable exosome bioimplant: a PPP-derived scaffold that retains exosomes locally, amplifies regenerative signaling, and enhances skin quality with natural, long-lasting outcomes.
Discover more: The First Exosome Bioimplant
